Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Serine/threonine-protein kinase involved in the control of the eukaryotic cell cycle, whose activity is controlled by an associated cyclin. Additionally we are shipping CDK14 Proteins (12) and and many more products for this protein.
Showing 10 out of 81 products:
Human Polyclonal CDK14 Primary Antibody for WB - ABIN1881191
Quina, Wang, Ng, Turner: Brn3a and Nurr1 mediate a gene regulatory pathway for habenula development. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2009
Show all 2 Pubmed References
Human Polyclonal CDK14 Primary Antibody for ICC, IF - ABIN4345007
Miyagaki, Yamasaki, Miyata, Takahashi, Kurokawa, Nakajima, Takiguchi, Fujiwara, Ishii, Tanaka, Mori, Doki: Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. in British journal of cancer 2012
MiR (show MLXIP Antibodies)-613 and CDK14 may serve as potential therapeutic targets for the treatment of glioma.
CDK14 mediated miR (show MLXIP Antibodies)-1202 to exert its anti-tumor effects.
CDK14 expression was closely associated with poor prognosis and overall survival of Osteosarcoma patients. miR (show MLXIP Antibodies)-216a inhibits CDK14 expression by binding to the 3'-untranslated region of CDK14.
PFTK1 expression is significantly higher in CRC (show CALR Antibodies) tissues compared with matched adjacent noncancerous colorectal tissues. The associations between PFTK1 expression and clinicopathological characters, and PFTK1 expression and the OS rate following resection suggested that PFTK1 may represent a novel biomarker of poor prognosis in CRC (show CALR Antibodies)
Results show that CDK14 and DYRK2 (show DYRK2 Antibodies) expression were inversely correlated in human breast cancer tissues and identified CDK14 as a target of DYRK2 (show DYRK2 Antibodies).
miR (show MLXIP Antibodies)-455 inhibits breast cancer cell proliferation through targeting CDK14
findings revealed an unrecognized role of Caprin-2 (show CAPRIN2 Antibodies) in facilitating LRP5 (show LRP5 Antibodies)/6 constitutive phosphorylation at G2/M through forming a quaternary complex with CDK14, Cyclin Y (show CCNY Antibodies), and LRP5 (show LRP5 Antibodies)/6.
these results suggest that knockdown of PFTK1 inhibited the proliferation and invasion of colon cancer cells as well as the EMT (show ITK Antibodies) progress by suppressing the Sonic hedgehog (show SHH Antibodies) signaling pathway.
we report that PFTK1 downregulation might inhibit the proliferation and invasion of NSCLC cells by suppressing the Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling pathway.
The expression level of PFTK1 was correlated with tumor grade, FIGO stage, lymph node metastasis of EOC patients as well as poor prognosis.
Cigarette smoke down regulates CDK14 levels and impairs Wnt (show WNT2 Antibodies) signaling.
may be a key regulator for thyrotropin-releasing hormone (TRH (show TRH Antibodies)) action in the cerebellum through the NO-cGMP pathway
Serine/threonine-protein kinase involved in the control of the eukaryotic cell cycle, whose activity is controlled by an associated cyclin. Acts as a cell-cycle regulator of Wnt signaling pathway during G2/M phase by mediating the phosphorylation of LRP6 at 'Ser-1490', leading to the activation of the Wnt signaling pathway. Acts as a regulator of cell cycle progression and cell proliferation via its interaction with CCDN3. Phosphorylates RB1 in vitro, however the relevance of such result remains to be confirmed in vivo. May also play a role in meiosis, neuron differentiation and may indirectly act as a negative regulator of insulin-responsive glucose transport.
PFTAIRE protein kinase 1
, cell division protein kinase 14
, serine/threonine-protein kinase PFTAIRE-1
, Cell division protein kinase 14